ANGPTL4 expression was reduced in CRC tissues and cells and was associated with poor prognosis of CRC patients. (A) Heatmap depicting partially significant differential gene expression in the CRC-associated gene expression microarray dataset GSE10950; x-axis indicates sample number, y-axis indicates gene name, left dendrogram indicates gene expression level cluster, upper dendrogram indicates sample cluster, each small square indicates the expression of a gene in a sample, and upper right histogram indicates color order (n = 24). (B) Differential gene expression analysis of ANGPTL4 in the GSE10950 microarray dataset; red box plots indicate tumor samples and gray box plots indicate normal samples, and the upper left corner is the corrected differential p-value (n = 24). (C) The expression levels of ANGPTL4 in CRC samples included in the TCGA database; the left side represents colon cancer and the right side represents rectal cancer, the red box plot indicates tumor samples, and the gray box plot indicates the normal samples (n = 24, * p < 0.05 vs. the tumor adjacent tissue). (D) RT-PCR analysis of mRNA expression of ANGPTL4 in CRC tissues (n = 67, * p < 0.05 vs. the para-carcinoma tissues). (E) Western blot analysis of protein levels of ANGPTL4 in CRC tissues, * p < 0.05 vs. the tumor adjacent tissue. (F) RT-qPCR determination of ANGPTL-4 mRNA expression levels in CRC cell lines, * p < 0.05 vs. the NCM460 cells. (G) Western blot analysis of ANGPTL-4 mRNA expression levels in CRC cell lines, * p < 0.05 vs. the NCM460 cells. (H) Survival rate determined by Kaplan-Meier survival curve analysis. All in vitro experiments were performed independently at least three times and the representative data were summarized as mean ± standard deviation. In RT-qPCR and western blot experiments, GAPDH served as the internal reference control. Comparisons were made using Student's t-test. *p < 0.05.